PDS Biotechnology Corp (PDSB) Short-Term Debt to Capital

Symbol and logo of brand PDS Biotechnology Corporation (PDSB)

The market trend for PDS Biotechnology (PDSB) demonstrates a value of 0.00, which is driven by the use of the Versamune platform to develop oncology drugs. Current price action is supported by expectations regarding the completion of final trials for cervical cancer therapy drugs. Meanwhile, the asset's high resilience is ensured by the specifics of its scientific niche, which remains independent of seasonal fluctuations or economic growth rates.

PDSB (pdsbiotech.com) Current Liabilities to Capital history from 07/04/2022 to 10/28/2026

Analytical breakdowns for PDS Biotechnology

- price and consensus price forecast:
Price Chart PDS Biotechnology|PDSB - Broker Consensus Forecast
- market capitalization data:
Market Capitalization PDS Biotech|PDSB - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share PDS Biotechnology|PDSB - Total Stockholders' Equity|Market Value to Book Value Ratio pdsbiotech.com|PDSB - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity PDS Biotechnology|PDSB - Long-Term Liabilities to Capital|Short-Term Debt to Capital PDS Biotechnology|PDSB - Company Total Indebtedness|Debt to Book Value PDS Biotech|PDSB - Long-Term Debt|Company Current Liabilities PDS Biotechnology
Fundamental company analysis:PDS Biotechnology Corporation (PDSB)
Manufactured products of PDS Biotechnology Corp

For PDS Biotechnology (PDSB), which is currently in the stage of costly clinical trials without market revenue, the short-term debt to equity chart reflects the dependence of development rates on short-term borrowing. This metric compares liabilities with a maturity of up to one year against equity, allowing investors to assess liquidity risk and the speed of debt accumulation under conditions of negative operating leverage.

Competitors of PDS Biotechnology

Short-Term Debt to Equity ImmunityBio Corp IBRX|Short-Term Debt to Capital Ratio Immunocore Corp (IMCR)|Janux Therapeutics - Short-Term Debt to Capital|arcusbio.com - Short-Term Debt to Equity Ratio|ZYME (Zymeworks) - Short-Term Debt to Equity|TNGX: Current Liabilities to Capital|Iovance (IOVA) - Short-Term Debt to Equity|IMTX (Immatics Biotechnologies) - Short-Term Debt to Equity|Short-Term Debt to Equity XNCR (Xencor, Inc.)|Current Liabilities to Capital compasstherapeutics.com|REPL: Short-Term Debt to Capital|Short-Term Indebtedness to Equity Lyell LYEL|IPHA: Short-Term Debt to Equity Ratio|PYXS - Current Liabilities to Capital|Short-Term Debt to Equity Ratio Compugen Limited (CGEN)|IOBT - Ratio of Short-Term Indebtedness to Capital|Sutro Biopharma - Short-Term Debt to Capital|INKT (MiNK Therapeutics Inc.) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity HOWL|Short-Term Debt to Equity Ratio IMMX|Short-Term Debt to Equity ALXO (ALX Oncology)|Short-Term Debt to Equity Ratio Cue Biopharma Inc. CUE|Short-Term Debt to Equity Ratio SONN (Sonnet BioTherapeutics Holdings)|MAIA Biotech - Short-Term Debt to Capital|Liminatus Pharma Corp (LIMN) - Short-Term Debt to Equity|LVTX: Short-Term Debt to Capital Ratio|Short-Term Debt to Equity NXTC|Current Liabilities to Capital Leap Therapeutics|Intensity Therapeutics Inc - Short-Term Debt to Equity Ratio|Short-Term Indebtedness to Equity Sensei Bio (SNSE)|Short-Term Debt to Equity Ratio Synthetic Biologics|Short-Term Loans to Capital Ratio gritstonebio.com (GRTS)|Short-Term Debt to Capital Kineta, Inc.|Ratio of Short-Term Indebtedness to Capital neximmune.com NEXI|TSBX (Turnstone Biologics Corporation) - Short-Term Debt to Capital|VCNX: Current Liabilities to Capital|Short-Term Debt to Equity Harpoon Tx HARP